Literature DB >> 31518426

The effect of tumour necrosis factor inhibitors on radiographic progression in axial spondyloarthritis: a systematic literature review.

Nadine Boers1, Celia A J Michielsens1, Désirée van der Heijde1, Alfons A den Broeder1, Paco M J Welsing1.   

Abstract

The effect of TNF-α inhibitors (TNFi), with or without concomitant NSAIDs, on radiographic progression in axial SpA remains unclear. Therefore, we performed a systematic literature review up to January 2019 to determine whether longer use of standard dose TNFi is superior vs lower duration or lower dose TNFi therapy, conventional synthetic DMARDs alone, or no therapy in inhibiting radiographic progression in patients with axial SpA. Our search yielded 373 titles of which 14 full text articles and five abstracts were eligible for quantitative analysis. Studies had an overall moderate to critical risk of bias. Data could not be pooled due to clinical and methodological heterogeneity. Individual studies showed conflicting results with mainly no significant difference in radiographic progression when comparing effect of TNFi therapy to no TNFi therapy or when comparing to less TNFi therapy until 2 years of follow-up. Results that are more significant are shown after 2 years' follow-up, mainly in subgroups with baseline syndesmophytes. Data on the additional or synergistic effect of concomitant NSAID use were inconclusive.
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  axial spondyloarthitis; non-steroidal anti-inflammatory drugs; radiographic progression; review; structural damage; tumour necrosis factor inhibitor

Mesh:

Substances:

Year:  2019        PMID: 31518426     DOI: 10.1093/rheumatology/kez363

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  5 in total

Review 1.  Juvenile Spondyloarthritis: What More Do We Know About HLA-B27, Enthesitis, and New Bone Formation?

Authors:  Shi Huan Tay; Joo Guan Yeo; Jing Yao Leong; Salvatore Albani; Thaschawee Arkachaisri
Journal:  Front Med (Lausanne)       Date:  2021-05-20

Review 2.  Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases.

Authors:  Harjit P Bhattoa; Zoltán Szekanecz; Boglárka Soós; Ágnes Szentpétery; Hennie G Raterman; Willem F Lems
Journal:  Nat Rev Rheumatol       Date:  2022-03-10       Impact factor: 20.543

3.  Treatment strategies in axial spondyloarthritis: what, when and how?

Authors:  George E Fragoulis; Stefan Siebert
Journal:  Rheumatology (Oxford)       Date:  2020-10-01       Impact factor: 7.580

4.  Sustained low disease activity measured by ASDAS slow radiographic spinal progression in axial spondyloarthritis patients treated with TNF-inhibitors: data from REGISPONSERBIO.

Authors:  Maria Llop; Mireia Moreno; Victoria Navarro-Compán; Xavier Juanola; Eugenio de Miguel; Raquel Almodóvar; Eduardo Cuende Quintana; Jesús Sanz Sanz; Emma Beltrán; M Dolores Ruiz Montesinos; Joan Calvet; Antoni Berenguer-Llergo; Jordi Gratacós
Journal:  Arthritis Res Ther       Date:  2022-01-21       Impact factor: 5.156

5.  Dual Blockade of TNF and IL-17A Inhibits Inflammation and Structural Damage in a Rat Model of Spondyloarthritis.

Authors:  Ihsan Hammoura; Renee H Fiechter; Shaughn H Bryant; Susan Westmoreland; Gillian Kingsbury; Wendy Waegell; Sander W Tas; Dominique L Baeten; Marleen G H van de Sande; Melissa N van Tok; Leonie M van Duivenvoorde
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.